Quoin Pharmaceuticals Ltd DRC Total Liabilities
Quoin Pharmaceuticals Ltd DRC total liabilities. Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has total liabilities worth $8.04 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check QNRX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Quoin Pharmaceuticals Ltd DRC (2015–2025)
Total liabilities of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. This chart illustrates how Quoin Pharmaceuticals Ltd DRC's total liabilities have evolved over time, based on quarterly financial data.
Quoin Pharmaceuticals Ltd DRC Competitors by Total Liabilities
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GRAFT POLYMER UK LS -001
F:J4I
|
Germany | €1.39 Million |
|
Millennium Silver Corp
V:MSC
|
Canada | CA$116.02K |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
Indonesia | Rp711.69 Billion |
|
Lite Access Technologies Inc
V:LTE
|
Canada | CA$27.15 Million |
|
Dovre Group Plc
HE:DOV1V
|
Finland | €71.17 Million |
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
USA | $4.78 Million |
|
Coloured Ties Capital Inc
V:TIE
|
Canada | CA$2.24 Million |
|
SG COMPANY S.P.A.
F:7KZ
|
Germany | €28.49 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Quoin Pharmaceuticals Ltd DRC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Quoin Pharmaceuticals Ltd DRC (QNRX) total assets.
Liquidity & Leverage Metrics
Quoin Pharmaceuticals Ltd DRC Total Liabilities Ratios Explained
Quoin Pharmaceuticals Ltd DRC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quoin Pharmaceuticals Ltd DRC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual total liabilities of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.27 Million | +11.78% |
| 2024-12-31 | $6.50 Million | -0.01% |
| 2023-12-31 | $6.51 Million | -7.74% |
| 2022-12-31 | $7.05 Million | -18.95% |
| 2021-12-31 | $8.70 Million | +8.95% |
| 2020-12-31 | $7.99 Million | +325.43% |
| 2019-12-31 | $1.88 Million | +4.45% |
| 2018-12-31 | $1.80 Million | -45.85% |
| 2017-12-31 | $3.32 Million | +135.52% |
| 2016-12-31 | $1.41 Million | +91.70% |
| 2015-12-31 | $735.02K | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more